21 news items
New Four-Year Sotyktu (deucravacitinib) Data Demonstrate Durable Response Rates and Consistent Safety in Moderate-to-Severe Plaque Psoriasis
BMY
16 May 24
, 0.9), major adverse cardiovascular events (Year 1, 0.3; Year 4, 0.3), venous thromboembolism (Year 1, 0.2; Year 4, 0.1) and deaths (Year 1, 0.2; Year
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approved by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma
BMY
15 May 24
with median duration of response not reached and the majority (77.1%) of responders in ongoing response at 18 months
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial
BMY
10 May 24
common types of lung cancer, representing up to 84% of diagnoses. Non-metastatic cases account for the majority of NSCLC diagnoses (approximately 60
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
BMY
26 Apr 24
the ureters and renal pelvis. The majority of urothelial carcinomas are diagnosed at an early stage, but approximately 50% of patients who undergo surgery
Bristol Myers Squibb Reports First Quarter Financial Results for 2024
BMY
25 Apr 24
Initiative to Deliver ~$1.5 Billion in Cost Savings, the Majority of Which Will be Reinvested to Fund Innovation and Drive Growth
4wykyo06v1p31tx3jl7fzft24fs78o6u927s13v5o82c1zuguo
AAL
AZN
BA
25 Apr 24
. “This is all in-line with our 2024 outlook that suggests the major equity indices are overvalued while the best opportunities are likely beneath
pkpcmfnfge z1y
BMY
15 Apr 24
Range
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between
c0bhr2t2g9j0eh2emztyc4 hti5qphpnxhke6axm7dy9phkf7fi092m
AGEN
BMY
12 Apr 24
this year and plans to present detailed Phase 2 efficacy results, including response durability and updated Phase 1 survival data, at a major medical
vwunvyg6hd 6m2hamf7fbs249o0uim91r8p062jqpmbmw0u9hrtys320
BMY
JNJ
MRK
10 Apr 24
. Already present across major European markets, Mainz Biomed continues to expand the international commercialization of ColoAlert®
uq37c1fo5wph2849lzrf28mfusulw754766s8g099a19rorjx exzeiaq7
BMY
8 Apr 24
experienced stability or improvements in key metabolic parameters over 52 weeks of treatment.
The majority of patients (65%) experienced
uxc9kqwwve3o9t6rvox4wtnqvor951pm6z81chnpmm1kmyc0fjv7cwmg0k
BMY
TSVT
5 Apr 24
showed a significant improvement in overall response rates (p<0.0001) with the majority (71%) of patients treated
m3947p92rr d914lprfg9lgmgi62mpobdmdsb33s8umg
BMY
25 Mar 24
received ELIQUIS had a statistically significant lower risk of stroke/systemic embolism (S/SE) and major bleeding (MB) than those patients who received
gzapjjpx08tw9 7gcdhior7np7hpvo
BMY
20 Mar 24
rate (ORR) with the majority (71.3% [95% CI: 65.7-76.8]) of patients treated with Abecma achieving